Pathological scars cause both local physical discomforts and mental disorders for patients. With the development of research, botulinum toxin type A (BTX-A) has been gradually used in the clinical treatment of scars. This article summarizes three potential mechanisms of BTX-A, including early tension reduction, inhibition of connective tissue hyperplasia, and alleviation of skin inflammation, as well as the clinical application of BTX-A in treating different types of scars. However, at present there is no uniform standard for the time, method, and proportioning of BTX-A injection for scar treatment, and there is also a lack of long-term follow-up results. Further researches are needed in future to clarify the mechanism of BTX-A in inhibiting scars, establish a uniform protocol of BTX-A injection, and provide a more effective treatment plan for scars.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: